Medicines Safety

This page will bring together all the PrescQIPP Medicines Safety resources. Each set of resources includes tools that can be adapted for local use before implementation.

If you have resources, you would like to share with the PrescQIPP community then please get in touch.

General resources

B260: Acute Kidney Injury (AKI) - Sick day guidance

This bulletin provides information on offering individualised sick day guidance to patients when they are well, so that they are able to proactively manage medication known to impair renal function during illness or fever and reduce the risk of AKI.

View > >

B248: Amiodarone and Dronedarone

This resource supports the implementation of the NHS England items which should not routinely be prescribed in primary care guidance.

View > >

B253. Anticholinergic burden

This bulletin discusses the review of treatment with anticholinergic drugs and the different scales available to support review. Support materials are available to identify the risk in patients and support appropriate action to reduce anticholinergic burden.

View > >

B242 : Appropriately switching anti epileptic drugs

This is an updated bulletin which includes new information on patient factors to consider before switching antiepileptic drugs, updated cost comparison charts and switch savings.

View > >

B172: Care homes Safeguarding and medicines

This bulletin discusses the issues around safeguarding in relation to medicines which could include: the deliberate withholding of medicine without a valid reason and incorrect use of medicines,

B194: Co-proxamol

This bulletin discusses the use of co-proxamol and supports reviewing and discontinuing prescribing in patients still taking this unlicensed medicine.

View > >

B256: Dependence forming medications

The dependence forming medicines (DFMs) resources provide an overview of DFMs and signpost to PrescQIPP resources which support medicines optimisation projects in this area.

View > >

B228: Emollients, paraffin content and fire risk

This bulletin aims to highlight the fire risk associated with emollient products and measures which need to be taken to reduce this risk.

View > >

B132: Fentanyl

This bulletin which is a DROP-List support bulletin will focus on fentanyl immediate-release formulations which has a NICE do not do as a first line treatment for breakthrough pain.

B258: Hypnotics

This bulletin offers advice on managing new patients with insomnia, recommends cost-effective prescribing choices, and encourages you to review chronic hypnotic users with a view to helping them withdraw from treatment.

View > >

B252: Medicines without harm

These resources support the implementation of local campaigns for the World Health Organisation (WHO) global patient safety challenge, medication without harm.

View > >

B245: Melatonin

This bulletin reviews the newly licensed melatonin preparations, unlicensed melatonin uses, safety concerns and treatment reviews.

View > >

B250: Modafinil

This bulletin and supporting materials review the place in therapy for modafinil in light of the MHRA restrictions on prescribing indications due to safety concerns.

View > >

B265: NSAIDs

These resources look at the safety implications of long term treatment with NSAIDs and support treatment initiation and review.

View > >

B267: PPIs - Long term safety and gastroprotection

This bulletin and implementation resources focus on reducing PPI prescribing for safety reasons by reviewing the continued need and stepping down or deprescribing where appropriate in line with current guidance.

View > >

B129: Role of Medication Safety Officers in CCGs

This bulletin and accompanying briefing highlight the key suggested roles and responsibilities for medication safety officers and medication device safety officers.

View > >

Webinars

Shared good practice - Award winning project webinars

Shared good practice - Other projects

Loading...